Argenx (ARGX) said Monday it has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the Vyvgart subcutaneous injection to treat adults with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy.
The company expects the European Commission to make a decision following the recommendation and the decision will apply to all 27 EU member states, and also to Iceland, Norway and Liechtenstein.
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.